Virological Rebound in Human Immunodeficiency Virus-infected Patients with or Without Residual Viraemia: Results from an Extended Follow-up
Overview
Authors
Affiliations
Human immunodeficiency virus (HIV) -infected patients with HIV RNA loads of < 50 copies/mL were followed-up for a median (interquartile range) of 30.8 (11.7-32.9) months to study the effect of residual viraemia (RV) on virological rebound (VR). At baseline, 446 (60.3%) patients had undetectable HIV RNA (group A) and 293 (39.7%) had RV (1-49 HIV RNA copies/mL, group B) by kinetic PCR. VR occurred in 4 (0.9%) patients in group A and in 12 (4.1%) patients in group B (p 0.007). Time to VR was shorter among patients of group B (Log-rank test: p 0.003). However, the proportion of VR was extremely low also among patients with RV.
Zhang J, Olatosi B, Yang X, Weissman S, Li Z, Hu J BMC Infect Dis. 2022; 22(1):122.
PMID: 35120435 PMC: 8817473. DOI: 10.1186/s12879-022-07047-5.
Lambert-Niclot S, Boyd A, Fofana D, Valin N, Wirden M, Meynard J Open Forum Infect Dis. 2019; 6(5):ofz177.
PMID: 31123690 PMC: 6524833. DOI: 10.1093/ofid/ofz177.
Gianotti N, Poli A, Galli L, Franzin M, Tadini P, Galizzi N PLoS One. 2017; 12(8):e0182007.
PMID: 28763473 PMC: 5538668. DOI: 10.1371/journal.pone.0182007.
Reduced adherence to antiretroviral therapy is associated with residual low-level viremia.
Maggiolo F, Di Filippo E, Comi L, Callegaro A, Colombo G, Di Matteo S Pragmat Obs Res. 2017; 8:91-97.
PMID: 28603436 PMC: 5457149. DOI: 10.2147/POR.S127974.
Amendola A, Pisciotta M, Aleo L, Ferraioli V, Angeletti C, Capobianchi M J Med Virol. 2016; 88(9):1535-44.
PMID: 26864171 PMC: 6585778. DOI: 10.1002/jmv.24493.